Post-Traumatic Stress Disorder

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

5 days ago talkbio0Tagged AFFIRM-1 phase 3 trial, BNC210, Clinical trial failure, Discontinuation (procedure), Merck, Neuphoria, Neuroscience discipline, Partnership, Phobia, Social, Post-Traumatic Stress Disorder, Programs - Publication Format, Schizophrenia

Neuphoria Therapeutics; BNC210; social anxiety disorder; AFFIRM-1 phase 3 trial; clinical trial failure; program discontinuation; PTSD; Merck partnership; Minerva Neurosciences; schizophrenia therapy

Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued

6 days ago talkbio0Tagged AFFIRM-1, BNC210, Clinical Failure, Neuphoria, Phobia, Social, Post-Traumatic Stress Disorder, strategic review

Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD

FDA Rejects Lundbeck and Otsuka’s Rexulti for PTSD on Insufficient Efficacy Evidence

1 month ago talkbio0Tagged brexpiprazole, Clinical Trials, Complete, Drug Approval, Lundbeck, Otsuka, Post-Traumatic Stress Disorder, Response Letter, Rexulti, sertraline, sNDA, United States Food and Drug Administration

FDA; Rexulti; Lundbeck; Otsuka; PTSD; brexpiprazole; sertraline; Complete Response Letter; sNDA; clinical trials; drug approval

FDA Advisory Committee Rejects Lundbeck and Otsuka’s PTSD Bid for Rexulti

3 months ago talkbio0Tagged Advisory Committees, brexpiprazole, Clinical Trials, drug efficacy, Lundbeck, Otsuka, Post-Traumatic Stress Disorder, Rexulti, sertraline, United States Food and Drug Administration

Lundbeck; Otsuka; Rexulti; FDA advisory committee; PTSD; brexpiprazole; sertraline; clinical trials; drug efficacy; setback

Transcend’s neuroplastogen posts positive mid-stage results in PTSD

7 months ago talkbio0Tagged CAPS-5, Placebos, Post-Traumatic Stress Disorder, Statistical Significance, TSND-201

TSND-201, Post-Traumatic Stress Disorder, Placebos, Statistical Significance, CAPS-5

FDA’s Rejection of Lykos’ MDMA-Assisted Therapy for PTSD: A Setback but Not a Roadblock for Psychedelic Research

1 year ago talkbio0Tagged Clinical Trials, ethical violations, Intact, Midomafetamine, Post-Traumatic Stress Disorder, psychedelic therapy, Rejection (Psychology), Science, United States Food and Drug Administration

MDMA, PTSD, Lykos Therapeutics, FDA rejection, psychedelic therapy, clinical trials, ethical violations, scientific integrity.

Lykos Faces Significant Setbacks as FDA Rejects MDMA Therapy and Three Studies Are Retracted Due to Unethical Conduct

1 year ago talkbio0Tagged Clinical Research, Lykos ', Midomafetamine, Post-Traumatic Stress Disorder, psychedelic research, Rejection (Psychology), unethical conduct, United States Food and Drug Administration

Lykos Therapeutics, MDMA therapy, FDA rejection, study retractions, unethical conduct, PTSD treatment, psychedelic research

Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment

1 year ago talkbio0Tagged Approved, Clinical Trials, CREM gene, Evidence, Inadequate (qualifier), Lykos ', Midomafetamine, Post-Traumatic Stress Disorder, United States Food and Drug Administration

Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval

FDA Advisory Panel Rejects Lykos’ MDMA Treatment for PTSD Despite Promising Results

1 year ago talkbio0Tagged Advisory Committees, Midomafetamine, Post-Traumatic Stress Disorder, psychedelic therapy, Psychopharmacologic Drugs, United States Food and Drug Administration

MDMA, PTSD, FDA, Lykos Therapeutics, Psychopharmacologic Drugs Advisory Committee, psychedelic therapy

Lykos Therapeutics’ MDMA-Assisted Therapy for PTSD: Awaiting FDA Advisory Committee Review

1 year ago talkbio0Tagged Advisory Committees, Clinical Trials, Drug Approval, Lykos ', MDMA-assisted therapy, Post-Traumatic Stress Disorder, United States Food and Drug Administration

Lykos Therapeutics, MDMA-assisted therapy, PTSD treatment, FDA Advisory Committee, clinical trials, drug approval process.